Exploring the Potential of Nano Drug Delivery Systems in Non-Small Cell Lung Cancer Treatment: Recent Developments and Perspectives

Ravinder      Verma; Neha      Minocha; Vineet      Mittal; Deepak      Kaushik

doi:10.2174/0115748855282418240220112042

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Globally, lung cancer ranks among the most frequent forms of tumor. The survival rate for people suffering from lung tumors after five years is only 20%, despite novel treatment options such as immunotherapy. Current therapies cause severe off-target effects and acquired drug resistance to explain the low survival rate. Identifying and developing new therapeutic approaches for lung cancer patients is crucial to improving the standard of care. As a result of the study, we researched clinical trials and experiments in fundamental research, and new approaches to drug delivery including adenoviruses, nanoparticles, and proteolysis-targeting chimeras (PROTACs). Several approaches can now be applied directly to lung cancer to prevent disease progression, including phosphatases, targeting protein kinases, protein modifications and ubiquitin ligases. In addition, the recent approval of Ribonucleic acid (RNA) based vaccines based on lipid nanoparticle technology has made it possible to improve current lung cancer treatments by combining chemo- and immunotherapies. This review emphasises recent advancements in pharmaceutical research aimed at developing technologies to target post-translational modifications in lung tumorigenesis. Elucidation of various scientific advances in conjunction with encouraging findings concerning therapies available, the future perspectives and challenges of nanocarriers for effective lung cancer are also presented in this article.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115748855282418240220112042	Print ISSN 1574-8855
Publisher Name Bentham Science Publisher	Online ISSN 2212-3903

Current Drug Therapy

Exploring the Potential of Nano Drug Delivery Systems in Non-Small Cell Lung Cancer Treatment: Recent Developments and Perspectives

Abstract Play Pause

Related Journals

Related Books

Abstract